Literature DB >> 1317799

Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.

A L Barry1, M A Pfaller, P C Fuchs.   

Abstract

The frequency of spontaneously occurring mutants resistant to 0.5, 1, 2, 4 and 8 micrograms of temafloxacin or ciprofloxacin per milliliter was documented with four Staphylococcus aureus and four Staphylococcus epidermidis strains. Resistant mutants were recovered at two- to four-fold the MIC of either drug, and they displayed cross-resistance to other fluoroquinolones. Resistance to temafloxacin occurred at frequencies lower than those observed with equal concentrations of ciprofloxacin. Resistance to greater than four-fold the MIC of either drug was not detected (frequencies less than 10(-10).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317799     DOI: 10.1007/bf02098088

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.

Authors:  A L Barry; P C Fuchs
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 5.  In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.

Authors:  F H Kayser; J Novak
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Increasing resistance of Staphylococcus aureus to ciprofloxacin.

Authors:  T E Daum; D R Schaberg; M S Terpenning; W S Sottile; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

7.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

8.  In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

Authors:  A L Barry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

9.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

10.  In vitro activity of ciprofloxacin against gram-positive cocci.

Authors:  A L Barry; R N Jones
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

  10 in total
  3 in total

1.  In vivo selection during pefloxacin therapy of a mutant of Staphylococcus aureus with two mechanisms of fluoroquinolone resistance.

Authors:  J Tankovic; N Desplaces; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 2.  Update on clinical significance of coagulase-negative staphylococci.

Authors:  W E Kloos; T L Bannerman
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

Review 3.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.